臨床外科70巻3号

2015年03月発行

特集 生検材料を手術に活かす 臓器別 癌診療における生検の役割

食道癌—治療前生検検体を用いた個別化医療の必要性

著者： 加藤健¹

所属機関： ¹国立がん研究センター中央病院消化管内科

ページ範囲：P.288 - P.292

【ポイント】
◆食道癌は手術，放射線，化学療法を用いた集学的治療を行う．
◆生検組織を用いた個別化医療により，患者のベネフィットを最大化できる．
◆マイクロアレイを用いた遺伝子発現解析による個別化医療の試みがなされている．

参考文献

1）The Japanese Society of Esophageal Disease：Comprehensive Registry of Esophageal Cancer in Japan, 3rd edition. 2002

2）Ando N, Kato H, Igaki H, et al：A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus（JCOG 9907）. Ann Surg Oncol 19：68-74, 2012

3）Kelsen DP, Ginsberg R, Pajak TF, et al：Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 339：1979-1984, 1998

4）Allum WH, Stenning SP, Bancewicz J, et al：Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 27：5062-5067, 2009

5）Tepper J, Krasna MJ, Niedzwiecki D, et al：Phase Ⅲ trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer：CALGB 9781. J Clin Oncol 26：1086-1092, 2008

6）van Hagen P, Hulshof MC, van Lanschot JJ, et al：Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366：2074-2084, 2012

7）Mariette C, Dahan L, Mornex F, et al：Surgery alone versus chemoradiotherapy followed by surgery for stage Ⅰ and Ⅱ esophageal cancer：final analysis of randomized controlled phase Ⅲ trial FFCD 9901. J Clin Oncol 32：2416-2422, 2014

8）Burmeister BH, Michael M, Burmeister E, et al：A randomized phase Ⅱ trial of two regimens of moderate dose chemoradiation therapy for patients with non-small cell lung cancer not suitable for curative therapy：Trans Tasman Radiation Oncology Study TROG 03.07. J Thorac Oncol 6：2076-2082, 2011

9）Hara H, Tahara M, Daiko H, et al：Phase Ⅱ feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104：1455-1460, 2013

10）Nakamura K, Kato K, Igaki H, et al：Three-arm phase Ⅲ trial comparing cisplatin plus 5-FU（CF）versus docetaxel, cisplatin plus 5-FU（DCF）versus radiotherapy with CF（CF-RT）as preoperative therapy for locally advanced esophageal cancer（JCOG 1109, NExT study）. Jpn J Clin Oncol 43：752-755, 2013

11）Kato K, Nakajima TE, Ito Y, et al：Phase Ⅱ study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage Ⅱ-Ⅲ esophageal carcinoma. Jpn J Clin Oncol 43：608-615, 2013

12）Tachimori Y：Role of salvage esophagectomy after definitive chemoradiotherapy. Gen Thorac Cardiovasc Surg 57：71-78, 2009

13）三梨桂子，武藤　学，佐々木博己：治療前生検の発現プロファイリングによる食道扁平上皮癌の内因性サブタイプの同定．Japan Digestive Disease Week （JDDW），2014

14）Makuuchi Y, Honda K, Osaka Y, et al：Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy. Cancer Sci 104：1045-1051, 2013

15）Wang MT, Chen G, An SJ, et al：Prognostic significance of cyclinD1 amplification and the co-alteration of cyclinD1/pRb/ppRb in patients with esophageal squamous cell carcinoma. Dis Esophagus 25：664-670, 2012

16）Shigaki H, Baba Y, Watanabe M, et al：PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Clin Cancer Res 19：2451-2459, 2013